Travere Therapeutics (NASDAQ:TVTX) lost ~5% premarket Friday after announcing a pause in enrollments in its Phase 3 HARMONY ...

We recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at ...

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Cubist Systematic Strategies LLC lessened its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by ...

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Travere Therapeutics (TVTX – Research Report), with ...

Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) and keeping the price ...

Travere Therapeutics offers rare kidney disease treatments with FDA-approved Filspari. Check out why I deem TVTX stock as a ...

The San Diego company said patients currently enrolled in pegtibatinase studies will continue to receive study medication from small-scale batches that aren't affected by the scale-up process, but it ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.51% of ...

Travere Therapeutics (TVTX) shares soared 11.6% in the last trading session to close at $15.23. The move was backed by solid volume with far more shares changing hands than in a normal session.

In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against the other best biotech stocks to buy under $20. The biotechnology industry is ...